Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024

MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):271-276. doi: 10.15585/mmwr.mm7312a5.ABSTRACTIn September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. As with past COVID-19 vaccines, additional doses may be considered for persons with immunocompromising conditions, who are at higher risk for severe COVID-19 and might have decreased response to vaccination. In this analysis, vaccine effectiveness (VE) of an updated COVID-19 vaccine dose against COVID-19-associated hospitalization was evaluated during September 2023-February 2024 using data from the VISION VE network. Among adults aged ≥18 years with immunocompromising conditions, VE against COVID-19-associated hospitalization was 38% in the 7-59 days after receipt of an updated vaccine dose and 34% in the 60-119 days after receipt of an updated dose. Few persons (18%) in this high-risk study population had received updated COVID-19 vaccine. All persons aged ≥6 months should receive updated 2023-2024 COVID-19 vaccination; persons with immunocompromising conditions may get additional updated COVID-19 vaccine doses ≥2 months after the last recommended COVID-19 vaccine.PMID:38547037 | PMC:PMC10986819 | DOI:10.15585/mmwr.mm7312a5

Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Ruth Link-Gelles Elizabeth A K Rowley Malini B DeSilva Kristin Dascomb Stephanie A Irving Nicola P Klein Shaun J Grannis Toan C Ong Zachary A Weber Katherine E Fleming-Dutra Charlene E McEvoy Omobosola Akinsete Daniel Bride Tamara Sheffield Allison L Nale Source Type: research